Imaging blood flow and glucose metabolism using PET
Single-tracer Multiparametric PET Imaging
This study is testing a new imaging method that looks at blood flow and sugar use in the body to see how it works for both healthy people and those with heart problems or cancer.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, Davis Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT06014515 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a single-tracer multiparametric PET imaging solution that simultaneously assesses blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG). The study will utilize tracer kinetic modeling to extract quantitative blood flow data from dynamic 18F-FDG PET scans. This approach is significant for understanding flow-metabolism relationships in various conditions, including ischemic cardiomyopathy and cancer. The study will involve both healthy volunteers and patients with cardiovascular diseases to evaluate the effectiveness of this imaging technique.
Who should consider this trial
Good fit: Ideal candidates include adults with cardiovascular, cardiometabolic, or cardiopulmonary diseases, as well as healthy volunteers without a history of related conditions.
Not a fit: Patients with active COVID-19 symptoms or those unable to comply with the study's fasting and lying requirements may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could enhance the assessment of tissue viability and treatment planning for patients with cardiovascular and metabolic diseases.
How similar studies have performed: Other studies have shown promise in using PET imaging for similar purposes, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Inclusion Criteria for all research participants: * Adults (age ≥ 18 years old) * Ability to understand and willingness to sign an informed consent form * Ability to adhere to the study visit schedule and other protocol requirements. * Willing and able to fast for at least 6 hours before and for the duration of the scan * No strenuous exercise for 24 hours prior to being scanned * Willing to lie on the scanner bed for up to 60 minutes * Free of active COVID-19 symptoms 2. Inclusion Criteria for healthy volunteers only: • Free of history of cardiovascular, inflammatory, infections or metabolic diseases that would result in changes in normal tissue perfusion and/or metabolism. 3. Inclusion Criteria for patients with disease: * Patients with clinically acute or chronic conditions such as cardiovascular, cardiometabolic, or cardiopulmonary diseases, which may include but are not limited to ischemic heart disease, myocarditis, arrhythmias, heart failure, nonalcoholic fatty liver disease, COVID-related sequala, diabetes, hypertension, or renal disease that would result in changes in normal tissue perfusion and/or metabolism. Exclusion Criteria: Participants are not eligible if they meet ANY of the following criteria: * Self-reported history of dysphoria or anxiety in closed spaces * Body weight \>240 kg due to limitations of the scanner bed * Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available) * Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG * Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only. * Prisoners * Any condition that would prevent the understanding or rendering of informed consent. * Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.
Where this trial is running
Sacramento, California
- UC Davis EXPLORER Molecular Imaging Center — Sacramento, California, United States (Recruiting)
Study contacts
- Principal investigator: Guobao Wang, PhD — University of California, Davis
- Study coordinator: Clinical Research Team
- Email: research-radiology-som@health.ucdavis.edu
- Phone: 916-731-9004
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.